Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

← catalyst calendar

NCT05330325

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
412actual
Sites
199
Countries
Austria, Belgium, Brazil +30

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-08-10actualWhen the study began enrolling
Primary completion2024-08-05actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-10-29estimatedThe whole study's end, after follow-up
First posted2022-04-15actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • SGA, Turner Syndrome, Noonan Syndrome, ISS

Interventions

  • Drug: Somapacitan
  • Drug: Norditropin®

Primary outcome

what the primary-completion date above is the date OF
Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS)
measured From baseline (week 0) to visit 7 (week 52)

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed